S-P Antifungals Promising
- Schering-Plough has identified a new azole antifungal agent, SCH56592, with potent activity against Aspergillus fumigatus, an important pathogen in immunocompromised patients. In vitro, the drug shows greater activity than amphotericin B (which is associated with a high rate of toxicity) and Janssen's itraconazole, while in vivo studies revealed that SCH56592 was active against itraconazole-resistant strains. Single rising-dose studies of the drug have now been completed, and multiple rising-dose studies are ongoing. A Phase II/III efficacy study is scheduled to get underway next year.
Meantime, S-P's lead azole antifungal voriconazole has entered Phase III trials and is scheduled for submission in 1997. This drug offers improved activity against filamentous fungi compared with fluconazole and itraconazole, as well as better central nervous system penetration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze